Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience

Linked article: This article is commented on by M. Scalvenzi et al ., pp. e146–e147 in this issue. To view this article visit https://doi.org/10.1111/jdv.15469 .